Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
Volume 1 |
Volume 2 |
Volume 3 |
Volume 4 |
|||
Series A: Cardiovascular |
Amazon $75 |
AS $75 |
AS $75 |
AS $75 |
||
Series A: Cardiovascular |
Volume 5:ALA $115 |
Volume 6:ALA $100 |
||||
Series B: Genomics |
AS $75 |
ALA $125 |
||||
Series C: Cancer |
AS $75 |
KP $100 |
||||
Series D: Immunology & Infectious Diseases |
AS $75 |
MS $115 |
||||
Series E: Patient-Centered Medicine |
MS $49 |
MS $75 |
AS $75 |
MS $75 |
UPDATED on 2/16/2020 – Calculations by Joel Shertok, PhD
SUMMARY for BioMed e-Series – Sixteen Volumes Series A:
100% $92,700,000 10% $9,270,000 35% to LPBI $3,244,500 _________________ Series B: 100% $200,000 10% $20,000 35% to LPBI $70,000 _________________ Series C: 100% $15,750,000 10% $1,575,000 35% to LPBI $551,250 _________________ Series D: 100% $23,375,000 10% $2,337,500 35% to LPBI $818,125 _______________ Series E: 100% $8,180,000 10% $818,000 35% to LPBI $286,300
GRAND TOTAL PROJECTED POTENTIAL REVENUES FROM BioMed e-Series: $4,970,175 |
VOL 6 | TTL |
$100 | $515 |
WORLD-WIDE | 180,000 |
$18,000,000 | $92,700,000 |
$1,800,000 | $9,270,000 |
$630,000 | $3,244,500 |
TTL | |
$200 | |
10,000 | |
$2,000,000 | |
$200,000 | |
$70,000 | |
TTL | |
$175 | |
WORLD-WIDE | 90,000 |
$15,750,000 | |
$1,575,000 | |
$551,250 | |
TTL | |
$190 | |
HEALTHCARE PROFS: VOL 2/3 | |
$23,375,000 | |
$2,337,500 | |
$818,125 | |
TTL | |
$274 | |
VOL 2, 3, 4 | |
$8,180,000 | |
$818,000 | |
$286,300 | |
TTL: | $4,970,175 |
GLOBAL MARKET PENETRATION eBOOKS | SERIES A, B, C, D, E | ||||||
SERIES A | CARDIOVASCULAR DISEASE | ||||||
VOL 1 | VOL 2 | VOL 3 | VOL 4 | VOL 5 | VOL 6 | TTL | |
PRICE/VOL | $75 | $75 | $75 | $75 | $115 | $100 | $515 |
ASSUME | 60,000 | CARDIOLOGISTS IN US; | 120,000 | WORLD-WIDE | 180,000 | ||
REVENUE = | $13,500,000 | $13,500,000 | $13,500,000 | $13,500,000 | $20,700,000 | $18,000,000 | $92,700,000 |
ASSUME | 10% | PENETRATION OF MARKET | |||||
REVENUE = | $1,350,000 | $1,350,000 | $1,350,000 | $1,350,000 | $2,070,000 | $1,800,000 | $9,270,000 |
ASSUME | LPBI SHARE = | 35% | |||||
REVENUE = | $472,500 | $472,500 | $472,500 | $472,500 | $724,500 | $630,000 | $3,244,500 |
SERIES B | GENOMICS | ||||||
VOL 1 | VOL 2 | TTL | |||||
PRICE/VOL | $75 | $125 | $200 | ||||
ASSUME | 10,000 | GENOMIC SPECIALISTS | 10,000 | ||||
REVENUE = | $750,000 | $1,250,000 | $2,000,000 | ||||
ASSUME | 10% | PENETRATION OF MARKET | |||||
REVENUE = | $75,000 | $125,000 | $200,000 | ||||
ASSUME | LPBI SHARE = | 35% | |||||
REVENUE = | $26,250 | $43,750 | $70,000 | ||||
SERIES C | CANCER | ||||||
VOL 1 | VOL 2 | TTL | |||||
PRICE/VOL | $75 | $100 | $175 | ||||
ASSUME | 30,000 | ONCOLOGISTS IN US; | 60,000 | WORLD-WIDE | 90,000 | ||
REVENUE = | $6,750,000 | $9,000,000 | $15,750,000 | ||||
ASSUME | 10% | PENETRATION OF MARKET | |||||
REVENUE = | $675,000 | $900,000 | $1,575,000 | ||||
ASSUME | LPBI SHARE = | 35% | |||||
REVENUE = | $236,250 | $315,000 | $551,250 | ||||
SERIES D | IMMUNOLOGY + INFECTIOUS DISEASES | ||||||
VOL 1 | VOL 2/3 | TTL | |||||
PRICE/VOL | $75 | $115 | $190 | ||||
ASSUME | 5,000 | ONCOLOGISTS IN US – VOL 1 | 200,000 | HEALTHCARE PROFS: VOL 2/3 | |||
REVENUE = | $375,000 | $23,000,000 | $23,375,000 | ||||
ASSUME | 10% | PENETRATION OF MARKET | |||||
REVENUE = | $37,500 | $2,300,000 | $2,337,500 | ||||
ASSUME | LPBI SHARE = | 35% | |||||
REVENUE = | $13,125 | $805,000 | $818,125 | ||||
SERIES E | PRECISION MEDICINE | ||||||
VOL 1 | VOL 2 | VOL 3 | VOL 4 | TTL | |||
PRICE/VOL | $49 | $75 | $75 | $75 | $274 | ||
ASSUME | 20,000 | VOL 1 | 32,000 | VOL 2, 3, 4 | |||
REVENUE = | $980,000 | $2,400,000 | $2,400,000 | $2,400,000 | $8,180,000 | ||
ASSUME | 10% | PENETRATION OF MARKET | |||||
REVENUE = | $98,000 | $240,000 | $240,000 | $240,000 | $818,000 | ||
ASSUME | LPBI SHARE = | 35% | |||||
REVENUE = | $34,300 | $84,000 | $84,000 | $84,000 | $286,300 | ||
TTL: | $4,970,175 |
Same numbers reached by another calculation
Assumptions |
Worldwide Sale Forecast:
Projected Sales under Assumptions and % Market Penetration |
LPBI EBITA: Royalties of 35% vs Amazon’s 65%
UNDER CONSERVATIVE FORECAST OF 10% Market Penetration |
Series A: Cardiovascular Disease
60,000 Cardiologists & Internists practicing Cardiology in the US & 120,000 Worldwide |
IF 100% Penetration in the US THEN
Volumes 1,2,3,4,5,6 60,000 x$515 = $30,900,000 IF 100% Penetration in the Worldwide THEN 120,000 x $515 = $61,800,000 US and WorldWide = $92,700,000 REALISTIC Penetration of 10% for Series A = $9,270,000 _____________________ |
LPBI’s share:
$3,244,500 per year |
Series B: Genomics
10,000 Genomics |
Volume 1:
10,000 x 1 x $75 = $750,000 Volume 2: 10,000 x 1 x $125 = $1,250,000 Total Series B: $2,000,000 REALISTIC penetration of 10% = $200,000 _____________________ |
LPBI’s share:
$70,000 per year |
Series C: Cancer
30,000 Oncologists in the US 60,000 Worldwide |
US
Volume 1: 30,000 x 1 x $75 = $2,250,000 + Volume 2: 30,000 x 1 x $100 = $3,000,000 $5,250,000 + Worldwide (60,000 x $175) = $10,500,000 Total Series C: $15,750,000 REALISTIC penetration of 10% = $1,575,000 _____________________ |
LPBI’s share:
$551,250 per year |
Series D: Immunology and Infectious Diseases
5,000 Immunologists & 200,000 Health Care professionals |
Volume 1:
[5,000 x 1 x $75 = $375,000] at REALISTIC 10% penetration = $37,500 + Volume 2&3: [200,000 x $115 = $23,000,000] Total Series D: $23,375,000 at REALISTIC 10% penetration = $37,500 + $2,300,000 = $2,337,500 _____________________ |
LPBI’s share:
$818,125 per year |
Series E: Precision Medicine
32,000 Readers |
Volumes 2,3.4:
32,000 x 3 x $75 =7,200,000 Volume 1: 20,000 x $49 = 980,000 [assumed Volume 1 had lower readership that Volumes 2,3,4] = $8,180,000 at REALISTIC penetration of 10% = $818,000 _____________________ |
LPBI’s share:
$286,300 per year |
|
SUMMARY for BioMed e-Series – Sixteen Volumes
Series A: 100% $92,700,000 10% $9,270,000 35% to LPBI $3,244,500 _________________ Series B: 100% $200,000 10% $20,000 35% to LPBI $70,000 _________________ Series C: 100% $15,750,000 10% $1,575,000 35% to LPBI $551,250 _________________ Series D: 100% $23,375,000 10% $2,337,500 35% to LPBI $818,125 _______________ Series E: 100% $8,180,000 10% $818,000 35% to LPBI $286,300
GRAND TOTAL PROJECTED POTENTIAL REVENUES FROM BioMed e-Series: $4,970,175 |
Penetration Levels for Series A,B,C,D,E: The entire BioMed e-Series
IF 10% Penetration >>>>> Total = $14,200,500
[100% Penetration $142,005,000]
Series A: $9,270,000
Series B: $200,000
Series C: $1,575,000
Series D: $2,337,500
Series E: $818,000
LPBI Royalties at 35%
LPBI’s Share for the entire BioMed e-series 16 Volumes: $4,970,175
Of note, for SERIES A: Cardiovascular Diseases – Six volumes:
- US plus Worldwide penetration rate at 100% has the potential of $92,700,000 Million !!!!!!!!!!!
- and at 10% level: $9,270,000 Million !!!!!!!!!!!
- LPBI Group’s 35% share LPBI’s share for Series A: $3,244,500 per year
LPBI’s Share for the entire BioMed e-series 16 Volumes: $4,970,175
Distribution Schedule of Obligations to Editors and Research Associates |
= 60% if 1 Editor; = 45% if 2 Editors; = 30% if 3 Editors
|
|
Comments:
Assertions:
Disclaimer: These figures represent a MODEL for an Acquirer of LPBI IP assets — not sales level that LPBI Group can achieve on our own related to compensations for Authors on Amazon.com under their Prime Membership policies activated since 2016 regarding the following two Programs which have deleterious effects on book sales and on compensation of Authors determined by Amazon. The Two Programs are:
For the Acquirer of LPBI’s IP Assets, we will pull out from Amazon all volumes, They will put their LABEL on and market all the volumes under their label, as done by their own Publishing House.
Use of LBPI Platform for Educational PurposesAuthor: Stephen J. Williams, PhD
Goal: to offer supplemental information for student lessons in an upper level Biology course on Cell Signaling and Cell Motility with emphasis on disease etiology including cancer, neurological disease, and cardiovascular disease. Course: Temple University Department of Biology course Cell Signaling and Motility Spring semester 2019. Forty five students enrolled. Methodology: Each weekly lesson was presented to students as a PowerPoint presentation. After each lesson the powerpoint presentation was originally meant to be disseminated to each class-registered student on the students Canvas account. Canvas is a cloud based Learning Management Software developed by educational technology company Salt Lake City, Utah company Infrastructure, Inc. According to rough figures, Canvas charges a setup fee and at least $30 per user (for a university the size of Temple University: 55,000 students at $30 each = 1.6 million a semester for user fees only). As a result of a technical issue with uploading the first week lesson on this system, I had informed the class that, as an alternative means, class presentation notes and lectures will be posted on the site www.pharmaceuticalintelligence.com as a separate post and searchable on all search engines including Google, Twitter, Yahoo, Bing, Facebook etc. In addition, I had informed the students that supplemental information, from curated posts and articles from our site, would be added to the class lecture post as supplemental information they could use for further reading on the material as well as helpful information and reference for class projects. The posted material was tagged with #TUBiol3373 (university abbreviation, department, course number) and disseminated to various social media platforms using our system. This allowed the students to enter #TUBiol3373 in any search engine to easily find their lecture notes and supplemental information. This gave students access to lectures on a mobile platform which was easily discoverable due to our ability to do search engine optimization. (#TUBiol3373 was among the first search results on most popular search engines).
Results (ongoing): After the first week, all 45 students used LBPI platform to access these lecture notes with 17 out of 45 continuing to refer to the site during every week (week 1-4) to the class notes. This was evident from our site statistics as well as number of downloads of the material. The students had used the #TUBIol3373 and were directed to the site mainly from search engines Google and Yahoo. In addition, students had also clicked on the links corresponding to supplemental information which I had included, from articles on our site. In addition, because of the ability to incorporate media on our site, additional information including instructional videos and interviews were included in lecture posts, and this material was easily updated on the instructor’s side. Adoption of the additional material from our site was outstanding, as many students had verbally said that the additional material was very useful in their studies. This was also evidenced by site statistics owing to the secondary clicks made from the class lecture post going to additional articles, some not even included as links on the original post. In addition, and more important, students had incorporated many of the information from the additional site articles posted and referenced in their class group projects. At end of semester a survey will be provided to assess the usefulness of such a teaching strategy. From a technical standpoint, the ease at which posts of this nature can be made as well as the ease of including links to full articles as references as well as media has been noted. Although students seem to navigate the Canvas software with ease, they had noticed many professors have issues or problems with using this software, especially with navigating the software for their needs. LBPI’s platform is an easily updated, accessible, and extensive knowledge system which can alleviate many of these technical issues and provide the added value of incorporating media based instructional material as well as downloadable file and allow the instructor ability to expound on the presented material with commentary. In addition due to the social nature of the platform, feedback can be attained by use of curated site statistics and commentary sections as well as online surveys. |